Discovery of a new biomarker for the mucopolysaccharidoses (MPS), dipeptidyl peptidase IV (DPP-IV; CD26), by SELDI-TOF mass spectrometry

Molecular Genetics and Metabolism

Volumn 96, Issue 4, 2009, Pages 218-224

  Beesley, Clare E ^a   Young, Elisabeth P ^a   Finnegan, Niamh ^b   Jackson, Marie ^c   Mills, Kevin ^a   Vellodi, Ashok ^b   Cleary, Maureen ^b   Winchester, Bryan G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Metabolic Medicine Unit   (United Kingdom)

^c Enzyme Laboratory   (United Kingdom)

Author keywords

Apolipoprotein CI and CI ; Biomarker; CD26; Dipeptidyl peptidase IV (DPP IV); Mucopolysaccharidoses (MPS); Surface enhanced laser desorption ionisation time of flight (SELDI TOF) mass spectrometry

Indexed keywords

APOLIPOPROTEIN C1; BIOLOGICAL MARKER; DIPEPTIDYL PEPTIDASE IV;

ADULT; AMINO TERMINAL SEQUENCE; ARTICLE; CATION EXCHANGE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REPLACEMENT; HUMAN; HURLER SYNDROME; METABOLIC REGULATION; MUCOPOLYSACCHARIDOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ADOLESCENT; ANTIGENS, CD26; APOLIPOPROTEIN C-I; BIOLOGICAL MARKERS; BLOOD PROTEINS; CASE-CONTROL STUDIES; HUMANS; MUCOPOLYSACCHARIDOSES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 61849105471     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2008.12.002     Document Type: Article

References (27)

1. Neufeld E.F., and Muenzer J. The Mucopolysaccharidoses. In: Scriver C.R., Beaudet A.L., and Sly W.S. (Eds). The Metabolic and Molecular Bases of Inherited Disease. eighth ed. (2001), McGraw-Hill, New York 3421-3452
2. Wraith J.E., Clarke L.A., Beck M., Kolodny E.H., Pastores G.M., Muenzer J., Rapoport D.M., Berger K.I., Swiedler S.J., Kakkis E.D., Braakman T., Chadbourne E., Walton-Bowen K., and Cox G.F. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-l-iduronidase (laronidase). J. Paediatr. 144 (2004) 581-588
3. Meunzer J., Gucsavas-Calikoglu M., McCandless S.E., Schuetz T.J., and Kimura A. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol. Genet. Metab. 90 (2007) 329-337
4. Harmatz P., Kramer W.G., Hopwood J.J., Simon J., Butensky E., and Swiedler S.J. Mucopolysaccharidosis VI Study Group, Pharmacokinetic profile of recombinant human N-acetylgalactosamine 4-sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): a phase I/II study. Acta. Paediatr. Suppl. 94 (2005) 61-68
5. Hollak C.E.M., van Weely S., van Oers M.H.J., and Aerts J.M.F.G. Marked elevation of plasma chitotriosidase activity. J. Clin. Invest. 93 (1994) 1288-1292
6. Boot R.G., Verhoek M., de Fost M., Hollak C.E.M., Maas M., Bleijlevens B., van Breemen M.J., van Meurs M., Boven L.A., Laman J.D., Moran M.T., Cox T.M., and Aerts J.M.F.G. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 103 (2004) 33-39
7. Siegel D.A., and Walkley S.U. Growth of ectopic dendrites on cortical pyramidal neurons in neuronal storage diseases correlates with abnormal accumulation of GM2 ganglioside. J. Neurochem. 62 (1994) 1852-1862
8. McGlynn R., Dobrenis K., and Walkley S.U. Differential subcellular localization of cholesterol, gangliosides, and glycosaminoglycans in murine models of mucopolysaccharide storage disorders. J. Comp. Neurol. 480 (2004) 415-426
9. Randall D.R., Sinclair G.B., Colobong K.E., Hetty E., and Clarke L.A. Heparin cofactor II-thrombin complex in MPS I: a biomarker of MPS disease. Mol. Genet. Metab. 88 (2006) 235-243
10. Randall D.R., Colobong K.E., Hemmelgarn H., Sinclair G.B., Hetty E., Thomas A., Bodamer O.A., Volkmar B., Fernhoff P.M., Casey R., Chan A.K., Mitchell G., Stockler S., Melancon S., Rupar T., and Clarke L.A. Heparin cofactor II-thrombin complex: a biomarker of MPS disease. Mol. Genet. Metab. 94 (2008) 456-461
11. J. Dirosario, E. Divers, C. Wang, J. Etter, A. Charrier, P. Jukkola, H. Auer, V. Best, D.L. Newsom, D.M. McCarty, H. Fu, Innate and adaptive immune activation in the brain of MPS IIIB mouse model, J. Neurosci. Res. (2008) (Epub ahead of print).
12. Kiehntopf M., Siegmund R., and Deufel T. Use of SELDI-TOF mass spectrometry for identification of new biomarkers: potential and limitations. Clin. Chem. Lab. Med. 45 (2007) 1435-1449
13. Bondarenko P.V., Cockrill S.L., Watkins L.K., Cruzado I.D., and MacFarlane R.D. Mass spectral study of polymorphism of the apolipoproteins of very low density lipoprotein. J. Lipid. Res. 40 (1999) 543-555
14. Handel T.M., Johnson Z., Crown S.E., Lau E.K., Sweeney M., and Proudfoot A.E. Regulation of protein function by glycosaminoglycans-as exemplified by chemokines. Ann. Rev. Biochem. 74 (2005) 385-410
15. Parish C.R. The role of heparan sulphate in inflammation. Nat. Rev. Immunol. 6 (2006) 633-643
16. Pan C., Nelson M.S., Reyes M., Koodie L., Brazil J.J., Stephenson E.J., Zhao R.C., Peters C., Selleck S.B., Stringer S.E., and Gupta P. Functional abnormalities of heparan sulfate in mucopolysaccharidosis-I are associated with defective biological activity of FGF-2 on human multipotent progenitor cells. Blood 106 (2005) 1956-1964
17. Gorrell M.D., Gysbers V., and McCaughan G.W. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand. J. Immunol. 54 (2001) 249-264
18. Boonacker E., and Van Noorden C.J.F. The multifunctional or moonlighting protein CD26/DPPIV. Eur. J. Cell Biol. 82 (2003) 53-73
19. Kubota T., Iizuka H., Bachovchin W.W., and Stollar B.D. Dipeptidyl peptidase IV (DP IV) activity in serum and on lymphocytes of MRL/Mp-lpr/lpr mice correlates with disease onset. Clin. Exp. Immunol. 96 (1994) 292-296
20. Steinbrecher A., Reinhold D., Quigley L., Gado A., Tresser N., Izikson L., Born I., Faust J., Neubert K., Martin R., Ansorge S., and Brocke S. Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo. J. Immunol. 166 (2001) 2041-2048
21. Firneisz G., Lakatos P.L., and Szalay F. Serum dipeptidyl peptidase IV (DPP IV, CD26) activity in chronic hepatitis C. Scand. J. Gastroenterol. 36 (2001) 877-880
22. Lakatos P.L., Firneisz G., Borcsiczky D., Zalatnai A., Selmeci L., and Szalay F. Elevated serum depeptidyl peptidase IV (CD26, EC 3.4.14.5) activity in experimental liver cirrhosis. Eur. J. Clin. Invest. 30 (2000) 793-797
23. Gotoh H., Hagihara M., Nagatsu T., Iwata H., and Miura T. Activity of dipeptidyl peptidase IV and post-proline cleaving enzyme in sera from osteoporotic patients. Clin. Chem. 34 (1988) 2499-2501
24. Ohnuma K., Dang N.H., and Morimoto C. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol. 29 (2008) 295-301
25. Rigante D., and Caradonna P. Secondary skeletal involvement in Sanfilippo syndrome. QJM 97 (2004) 205-209
26. Shachter N.S. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr. Opin. Lipidol. 12 (2001) 297-304
27. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul. Pept. 85 (1999) 9-24